Cancer specialist Tessera Diagnostics raises $3 million:
This article was originally published in Clinica
Executive Summary
Tessera Diagnostics, a Seattle, Washington-based start-up focusing on cancer, has raised $3.2m in a series A financing round, exceeding its target of $1.75m. Following the initial closing of the round last April, the company started a funded research programme at the University of Pittsburgh. Originally it had access to prostate specific cancer markers; it has now gained an option on colon cancer markers from the university. Tessera is developing highly specific early-stage cancer diagnostics, and is seeking partners for other applications of its markers in imaging, therapeutics and drug discovery. It was founded by president and CEO Robert Masterson and chairman Raymond Cairncross.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.